F8 and hemophilia A: The development of neutralizing antibodies (inhibitors) against factor VIII (FVIII) occurs in 25%‐40% of patients with severe haemophilia A.1, 2, 3, 4, 5 Persons with haemophilia A who develop high‐titre inhibitors (HTI) become resistant to FVIII replacement therapy.